
    
      This is a Phase 1, randomised, double-blind, double-dummy, cross-over trial to assess the
      bronchodilation effect of a single dose of LAS40468 and a single dose of
      salmeterol/fluticasone propionate (SeretideÂ®) administered to adult patients with stable
      asthma.

      The study will consist of a screening visit and treatment periods of approximately 13 hours
      separated by washout periods of 7 to 14 days from the time of Investigational Medicinal
      product (IMP) administration.
    
  